Datieva, V K, Rosinskaia, A V, Levin, O S · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2013
This study tested whether melatonin, a natural hormone that helps regulate sleep, could help Parkinson's disease patients who also experience chronic fatigue. Thirty patients took melatonin and showed a 21% improvement in fatigue, better sleep, less anxiety, and improved quality of life. The treatment did not significantly affect movement problems, thinking abilities, or depression.
Chronic fatigue affects approximately 50% of Parkinson's disease patients and remains poorly treated. Since ME/CFS shares fatigue and circadian dysfunction with PD-related fatigue, understanding melatonin's efficacy in this population may inform novel therapeutic approaches for primary CFS. This work suggests circadian pathway interventions warrant further investigation in post-viral and idiopathic fatigue syndromes.
This study cannot establish that melatonin is effective for ME/CFS specifically, as the cohort consisted exclusively of Parkinson's disease patients with secondary fatigue. The lack of a randomized control arm or blinding means improvements could reflect placebo effect, natural disease course, or confounding effects from optimized antiparkinsonian medications. Findings cannot be generalized to primary CFS without dedicated controlled trials.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.